BridgeMD
New treatment option for Dissecting Aneurysm of Cerebral Artery
Official title Metformin in Patients With Unruptured Vertebrobasilar Dissecting Aneurysms (METTLE)
ClinicalTrials.gov ID: NCT06405971
What this study is testing
What is Metformin?
Metformin is an investigational medicine, given as a pill taken by mouth, being studied as a potential treatment for dissecting aneurysm of cerebral artery.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Vertebrobasilar dissecting aneurysms (VBDAs) are one of the most important causes of stroke in young and middle-aged people, and the natural history of VBDAs is complex and varied, often leading to high rates of disability and mortality. For some patients with VBDAs who are not suitable for surgical entrapment and intervention, pharmacologic therapy may be used to slow the progression of VBDAs.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Age ≥18 years and ≤75 years, gender is not limited;
- Patients with previously untreated, unruptured stable VBDAs clearly diagnosed by DSA, CTA or MRA;
- Patients with aneurysm wall enhancement as shown by HR-VWI of 3.0T high field strength MRI whole body scanner at Tsinghua University;
- Baseline mRS score ≤2;
- Patients voluntarily participated in this study and signed an informed consent form.
You likely can't join if
- Patients with aneurysms located in non-vertebral basilar artery sites (mainly referring to bifurcation saccular aneurysms);
- Patients with combined diabetes or its complications;
- Patients who are allergic to any components in MET;
- Pregnant and lactating female patients;
- Patients with other immune diseases in combination, patients taking immunosuppressants or anti-inflammatory drugs (such as long-term use of aspirin...
- Target aneurysm-related symptoms were severe at the time of diagnosis, and the mRS score was ≥3;
See the full eligibility criteria
- Age ≥18 years and ≤75 years, gender is not limited;
- Patients with previously untreated, unruptured stable VBDAs clearly diagnosed by DSA, CTA or MRA;
- Patients with aneurysm wall enhancement as shown by HR-VWI of 3.0T high field strength MRI whole body scanner at Tsinghua University;
- Baseline mRS score ≤2;
- Patients voluntarily participated in this study and signed an informed consent form.
- Patients with aneurysms located in non-vertebral basilar artery sites (mainly referring to bifurcation saccular aneurysms);
- Patients with combined diabetes or its complications;
- Patients who are allergic to any components in MET;
- Pregnant and lactating female patients;
- Patients with other immune diseases in combination, patients taking immunosuppressants or anti-inflammatory drugs (such as long-term use of aspirin, statin, hormones and other drugs);
- Target aneurysm-related symptoms were severe at the time of diagnosis, and the mRS score was ≥3;
- VBDAs have received treatment or surgical treatment;
- Those with severe allergy to the contrast agent gadolinium terlumate glucosamine (Gd-DTPA) (skin rash not counted);
- Those with severe renal disease resulting in renal insufficiency (glomerular filtration rate \<30ml/(min 1.73m2));
- Patients with metal implants in the body (e.g., cardiac stents, cardiac prosthetic valves, pacemakers, metal joints, steel plates, non-removable metal dentures, etc.);
- Patients known to suffer from dementia or psychiatric disorders and claustrophobia who are unable to complete the magnetic resonance examination;
- Patients with other serious diseases combined at the time of diagnosis and with an expected survival time of less than 1 year;
- Patients who are participating in clinical trials of other drugs or devices.
- Other conditions judged by the investigator to exist that are unsuitable for enrollment.
The study team makes the final eligibility decision.
Where it's taking place
- Beijing, Beijing Municipality, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Beijing, Beijing Municipality, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.